

# “From IP to IPO”



**Prof Jun WANG**  
**CEO**  
**GeneHarbor (Hong Kong) Biotechnologies Ltd**

**Date :** 27 July 2018

**Time :** 11:00am to 12:00noon

**Venue :** Room B5-308, Blue Zone, 5/F, Yeung Kin Man Academic Building

## **Abstract**

In this three-part presentation, Professor Wang will first highlight the recent discoveries that hallmark NAD<sup>+</sup> (nicotinamide adenosine dinucleotide) as a key player in longevity; and the development and application of NMN (nicotinamide mononucleotide), the immediate precursor of NAD<sup>+</sup>, as an anti-aging agent. He then outlines the recent industrial applications of in vitro enzymatic synthesis at GeneHarbor, a company he found 14 years ago. Finally, Professor Wang catalogs the similarities and disparities of in vitro enzymatic synthesis and synthetic biology.

## **About the Speaker**

Professor Jun WANG was a professor in the Biochemistry Department of CUHK until 2003, when he left the university to start GeneHarbor (Hong Kong) Biotechnologies Ltd, where he remains as CEO of the company. Focusing on the development and deployment of in vitro enzymatic synthesis at industrial scale, he and his colleagues have invented a number of commercially viable manufacture processes for the production of a dozen of highly value-added API and nutritional products. Professor WANG is Adjunct Professor at CUHK and a tutor of HKX Technology Fund.

Enquiry:

Mr Edward Lau (3442-6223, [eduarlau@cityu.edu.hk](mailto:eduarlau@cityu.edu.hk))

Miss Natalie Wong (3442-4902, [natalie.w@cityu.edu.hk](mailto:natalie.w@cityu.edu.hk))